Concerns Mount Over Safety of Compounded GLP-1 Medications Amid Regulatory Scrutiny

A recent publication highlights ongoing concerns regarding the safety of compounded glucagon-like peptide-1 (GLP-1) receptor agonists, medications used for diabetes and obesity. The discussion references a recall of compounded tirzepatide injections by Apothecary Pharma in October due to sterility concerns, following an FDA warning letter citing significant deficiencies in the pharmacy's sterile-drug production. Unlike FDA-approved drugs, compounded versions do not undergo the same rigorous premarket review for safety, effectiveness, and quality. While compounding pharmacies aim to address patient needs and affordability, a 2026 study identified a previously unreported impurity in sampled compounded tirzepatide-vitamin B12 products, and adverse-event analyses show higher reporting odds for contamination and manufacturing problems with compounded products.